129 related articles for article (PubMed ID: 35853753)
1. Cancer stem cell markers interplay with chemoresistance in triple negative breast cancer: A therapeutic perspective.
Babu SPP; Venkatabalasubramanian S; Munisankar SR; Thiyagaraj A
Bull Cancer; 2022 Sep; 109(9):960-971. PubMed ID: 35853753
[TBL] [Abstract][Full Text] [Related]
2. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
3. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
[TBL] [Abstract][Full Text] [Related]
4. Induction of AMPK activation by N,N'-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers.
Johnson J; Rychahou P; Sviripa VM; Weiss HL; Liu C; Watt DS; Evers BM
PLoS One; 2019; 14(3):e0209392. PubMed ID: 30875375
[TBL] [Abstract][Full Text] [Related]
5. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
Ring A; Kaur P; Lang JE
BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
7. An insight into the cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
Qayoom H; Wani NA; Alshehri B; Mir MA
Future Oncol; 2021 Nov; 17(31):4185-4206. PubMed ID: 34342489
[TBL] [Abstract][Full Text] [Related]
8. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer.
Bousquet G; El Bouchtaoui M; Sophie T; Leboeuf C; de Bazelaire C; Ratajczak P; Giacchetti S; de Roquancourt A; Bertheau P; Verneuil L; Feugeas JP; Espié M; Janin A
Oncotarget; 2017 May; 8(21):35205-35221. PubMed ID: 28445132
[TBL] [Abstract][Full Text] [Related]
9. BOP1 confers chemoresistance of triple-negative breast cancer by promoting CBP-mediated β-catenin acetylation.
Li S; Wu H; Huang X; Jian Y; Kong L; Xu H; Ouyang Y; Chen X; Wu G; Yu L; Wang X
J Pathol; 2021 Jul; 254(3):265-278. PubMed ID: 33797754
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
[TBL] [Abstract][Full Text] [Related]
12. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
He J; Lee HJ; Saha S; Ruan D; Guo H; Chan CH
Cell Death Dis; 2019 Mar; 10(4):285. PubMed ID: 30918246
[TBL] [Abstract][Full Text] [Related]
14. AMPK inhibits MTDH expression via GSK3β and SIRT1 activation: potential role in triple negative breast cancer cell proliferation.
Gollavilli PN; Kanugula AK; Koyyada R; Karnewar S; Neeli PK; Kotamraju S
FEBS J; 2015 Oct; 282(20):3971-85. PubMed ID: 26236947
[TBL] [Abstract][Full Text] [Related]
15. p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
Qi X; Yin N; Ma S; Lepp A; Tang J; Jing W; Johnson B; Dwinell MB; Chitambar CR; Chen G
Stem Cells; 2015 Sep; 33(9):2738-47. PubMed ID: 26077647
[TBL] [Abstract][Full Text] [Related]
16. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
[TBL] [Abstract][Full Text] [Related]
17. Molecular targets and therapeutics in chemoresistance of triple-negative breast cancer.
Nath A; Mitra S; Mistry T; Pal R; Nasare VD
Med Oncol; 2021 Nov; 39(1):14. PubMed ID: 34812991
[TBL] [Abstract][Full Text] [Related]
18. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer.
Doherty MR; Cheon H; Junk DJ; Vinayak S; Varadan V; Telli ML; Ford JM; Stark GR; Jackson MW
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):13792-13797. PubMed ID: 29229854
[TBL] [Abstract][Full Text] [Related]
19. MYC Inhibition Depletes Cancer Stem-like Cells in Triple-Negative Breast Cancer.
Yang A; Qin S; Schulte BA; Ethier SP; Tew KD; Wang GY
Cancer Res; 2017 Dec; 77(23):6641-6650. PubMed ID: 28951456
[TBL] [Abstract][Full Text] [Related]
20. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]